Genisphere is a life science company providing proprietary targeted delivery of therapeutics. As a nanotechnology company, it has created an innovative DNA-based targeted drug delivery platform called 3DNA®. Genisphere seeks additional partnerships with biotechnology and pharmaceutical companies that could benefit from the company's platform technology, which is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids in a highly targeted manner. Originally the nanoparticle was used to deliver signal and amplify the sensitivity of diagnostics tests. About three years ago, the nanoparticle was adapted as a targeted drug delivery vehicle and a significant option-to-license agreement has been executed with MedImmune. There are also a number of additional large pharmaceutical firms evaluating the technology.Read case study
Pope Housing provides temporary housing to individuals, families and businesses requiring an on-site housing solution, generally due to fire. Operates across New England and Eastern New York State. Losing a home to a natural catastrophe can be devastating. For 35 years, Pope Housing has helped families – displaced by fire, flood or storm – quickly return to a normal living environment by placing a quality temporary mobile home or trailer right on their own property while their home is rebuilt. Pope also provides temporary mobile housing to families building or renovating their homes and to commercial clients and municipalities during building renovations.
AllerGenis is a medical diagnostic company developing a targeted allergy blood test to better assess , diagnose, and manage food-borne allergies. AllerGenis addresses a central challenge which clinicians face when diagnosing and treating patients with food allergies by identifying the proteins found in food believed to induce an allergic response. The Company’s novel diagnostic platform further addresses the limitation of existing allergy tests which do not provide a measure of how strongly an allergen stimulates such a response. The AllerGenis blood test delivers an individualized reaction pattern or “fingerprint” that provides substantially more detail about a patient’s allergy than current diagnostic procedures or tests. AllerGenis plans to sell directly to specialty physician practices, and other clinical care centers, in addition to pursuing licensing and commercialization agreements with therapeutic and food manufacturing partners.
Visit the AllerGenis website here.
Founded in 2000, EnergyWatch is a market leader in utility data analytics and reporting for multiple real estate markets: commercial and corporate real estate, industrial and manufacturing, big box retail, education, government facilities and others. EnergyWatch and its SaaS watchwire platform provide descriptive, predictive, and prescriptive analytics and tools to; identify and analyze the interactive effects of operational and capital improvements on utility supply and delivery costs; measure, verify, and report on key performance indicators; strategically procure energy and understand energy rates; and summarize the results for key decision makers.
Ask Corporate Fuel
Contact us to find out how Corporate Fuel can help you realize the full value of your businessContact Us Today